Zhitong Finance App News, Tianjin Pharmaceutical (600488.SH) issued an announcement. Recently, the company's subsidiary Hubei Jinyao Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for tranexamic acid sodium chloride injection approved and issued by the State Drug Administration.

Tranexamic acid sodium chloride injection is mainly used for all kinds of bleeding caused by acute or chronic, localized or systemic primary fibrinolysis. In November 2024, Hubei Jinyao submitted an application for registration and marketing license for domestically produced drugs to the Drug Evaluation Center of the State Drug Administration and was accepted, and a drug registration certificate issued by the State Drug Administration was obtained in August 2026. Up to now, Hubei Jinyao has invested a total of about 3.6 million yuan in research and development in the tranexamic acid sodium chloride injection project.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.